Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.05, read 2026-10-28
Ethical passes the values gate
Price6.63 USD
Fair value4.60
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markup4.20+57.9% to today ✓Accumulation gives way to Markup first Markup read since September
2026-10-02Read Accumulation4.01+65.3% to today ✓Markup gives way to Accumulation after a 24% rise in 4 weeks
2026-09-06Read Markup3.23+105.3% to today ✓Distribution gives way to Markup after a 25% slide in 9 weeks
2026-07-02Read Distribution4.33+53.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Myriad Genetics Inc holds its Markup at $6.63. The statistical read favours the buyers, held for 3 days.
As held on the ledger · 2026-10-28
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 3 days
Price at the screen
$6.63
Valuation
N/A trailing · -9.89 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.64
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.69%
Below 33%
Interest-bearing debt is just 29.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
37.49%
Below 49%
Money owed to the company is 37.5% of assets, under the 49% limit.
Pass
Revenue purity
0.22%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Myriad Genetics clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MYGN's ethical verdict changes
Today MYGN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 30.6% above the base estimate.
Third-party analyst targets: 8 covering, consensus Hold. The average target sits −31% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MYGN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup$6.63+13.9%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$5.82+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$5.82+33.8%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 33.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
2026-10-18Markup$4.35+3.6%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
2026-10-11Markup · changed$4.20+4.7%Entry 7
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 24.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
2026-09-06Markup · changed$3.23-47.7%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 47.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
2026-08-06Distribution$6.18+42.7%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 42.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
2026-07-18Distribution$4.33+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (8 analysts) rates it none, with a mean price target of $6.
2026-07-03Distribution$4.33+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.